Undeniable Facts About Stock?: CSG Systems International (CSGS), Catabasis Pharmaceuticals (CATB)

CSG Systems International (CSGS) stock observed with a volume of 304370 in the Friday trading period as compared to its average volume of 164.6K shares over the last three months period. CSGS recorded change of 1.21% and recent share price is observed at $36.71. It’s relative volume stands at 1.85. Floating shares were 32.82 million in the market and outstanding shares were 33.21 million. The Company has market Cap of $1219.14M.

The stock performance indicator shows that how much stock have changed over the specific recent trading period. This snap also identify the up or down movement in specific trading period .WEEKLY performance of the stock was 1.75% and MONTHLY performance was 1.63% and YEARLY performance was -15.86%. YEAR TO DATE performance was at -16.23%. Price changed for the last THREE MONTHS around -1.13% however performance for the SIX MONTHS is noted at -6.16%. Currently 1.70% of shares owned by company management and 99.46% of shares possessed by institutional investors.

The analysis of stock closing price and mean price of some specific trading days shows the price movement whether it is bullish or bearish and up or down trend. The stock price as close of last trading session is going at 3.13% looking mean price of last 20 days, and price is moving at -2.73% from mean price of last 50 days, and price is at -11.49% from mean price of last 200 days.

CSG Systems International (CSGS) recently performed at -12.72% to its 50-day high and moved 10.14% from the 50-day low. Taking a One Year look, the current stock price from the one year high is -24.81%, and the separation from the one year low is presently at 10.14%. The Average True Range (ATR) which measure volatility is standing at 1.12. The stock price disclosed 3.01% volatility in past month and identified 4.25% volatility for the past week. Beta factor was noted at 0.87. Beta measures the riskiness of the security. High beta >1 means higher risky and low beta <1 shows low riskiness.

The Profitability ratios reveals facts about how much stock is profitable and what the past Profitability performance. Tracking twelve months period, Return on investment (ROI) remarked at 12.10% and Return on equity (ROE) noticed at 17.10% while Return on asset (ROA) noted at 6.50%. The stock Gross margin detected at 49.90%.Operating margin of the company spotted 12.60%. Operating margin is a measurement of what proportion of a company’s revenue is left over after paying for variable costs of production such as wages, raw materials, etc. and For the last 12 months, Net Profit Margin stayed at 7.20%. Net Profit measures how much out of every dollar of sales a company actually keeps in earnings. The Company holds dividend yield of 2.29% with Payout Ratio of 45.20%.

The Company expected to achieve EPS growth for this year with 1.70% and estimated to reach at 8.03% EPS growth for next year. EPS growth for past five years was at 5.20% while expectation for the next 5-years, earning per share will grow at -5.00%. Sales growth past 5 years was observed at 0.80% and Sales growth quarter over quarter is 10.50%. The company declared 1.85 EPS (ttm). EPS growth quarter over quarter is at 30.90%. EPS serves as an indicator of a company’s profitability and is generally considered to be the single most important variable in determining a share’s price. The company has price to earnings (P/E) ratio of 19.85. Forward P/E is standing at 11.86.

Catabasis Pharmaceuticals (CATB) stock traded a volume of 181236 shares in the Friday trading period as compared to its average volume of 979.54K shares over the last three months period. CATB revealed change of -1.43%and stock price is seen at $0.69. It’s relative volume stands at 0.19. Floating shares were 68.05 million in the market and outstanding shares were 73.79 million. The Company has market Cap of $0M.

The Profitability ratios reveals facts about how much stock is profitable and what the past Profitability performance. Tracking twelve months period, Return on investment (ROI) remarked at -189.50% and Return on equity (ROE) noticed at -123.70% while Return on asset (ROA) noted at -96.60%. Net Profit measures how much out of every dollar of sales a company actually keeps in earnings.

The analysis of stock closing price and mean price of some specific trading days shows the price movement whether it is bullish or bearish and up or down trend. The stock price as close of last trading session is going at 3.11% looking mean price of last 20 days, and price is moving at -6.38% from mean price of last 50 days, and price is at -42.82% from mean price of last 200 days.

The stock performance indicator shows that how much stock have changed over the specific recent trading period. This snap also identify the up or down movement in specific trading period .WEEKLY performance of the stock was 4.55% and MONTHLY performance was -4.72% and YEARLY performance was -63.30%. YEAR TO DATE performance was at -53.69%. Price changed for the last THREE MONTHS around 5.67% however performance for the SIX MONTHS is noted at -57.93%. Currently 4.20% of shares owned by company management and 52.70% of shares possessed by institutional investors.

Catabasis Pharmaceuticals (CATB) recently performed at -21.59% to its 50-day high and moved 12.18% from the 50-day low. Taking a One Year look, the current stock price from the one year high is -71.01%, and the separation from the one year low is presently at 13.11%. The Average True Range (ATR) which measure volatility is standing at 0.04. The stock price disclosed 6.99% volatility in past month and identified 5.19% volatility for the past week. Beta factor was noted at 0.81. Beta measures the riskiness of the security. High beta >1 means higher risky and low beta <1 shows low riskiness.

The Company expected to achieve EPS growth for this year with 43.20% and estimated to reach at 17.60% EPS growth for next year. EPS growth for past five years was at -2.20%. Sales growth quarter over quarter is . The company declared -1.03 EPS (ttm). EPS growth quarter over quarter is at 38.10%. EPS serves as an indicator of a company’s profitability and is generally considered to be the single most important variable in determining a share’s price.

Adrian Lamb, a graduate of University of Sydney and has two years’ experience of Wall Street Investor. He has an experience in Journalism and Content Writing, love writing stories full of efficient language and accurate content. His articles are published on Seeking Alpha, The Street, and The Motley Fool. Adrian has over 4 year experience as a news writer. Previously, he worked as a tech news reporter. He covers Business news category.

Leave a Reply

Your email address will not be published. Required fields are marked *